EGFR and non-small cell lung carcinoma: Considering the positive pre-clinical data, addition of autophagy inhibitor (HCQ) to standard of care erlotinib is currently being evaluated in patients with mutant or high expressing EGFR NSCLC tumors (NCT00977470 [156]).